March 20, 2017
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Omeros reports $66.7 million net loss in 2016
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Omeros reported a net loss of $19.6 million, or $0.45 per share, in the fourth quarter of 2016, compared with a net loss of $19.8 million, or $0.52 per share, in 2015’s fourth quarter.
For the full year, the company reported a net loss of $66.7 million, or $1.65 per share, compared with a net loss of $75.1 million, or $2 per share, in 2015, according to a company press release.
The company reported $41.6 million in revenues in 2016, compared with $13.5 million in 2015, with $12.9 million in revenue from Omidria (phenylephrine 1% and ketorolac 0.3% injection) sales reported in the fourth quarter.
Total costs and expenses were up $11.1 million in 2016 to $95.9 million, attributed mostly to a lawsuit and increased employee costs.